Company: CRNX
Filing Date: 2025-01-14
Form Type: 8-K
Source: 0000950170-25-005435
Chunk: 0

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-01-14
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On January 14, 2025 at 4:30 pm Pacific Time, Scott Struthers, Ph. D., Founder and Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “ Company,” “ Crinetics,” “we,” “us,” or “our”), will present a Company update at the 43rd annual J. P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 13-16, 2025. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events & Presentations section of the Company’s website or directly on the J. P. Morgan virtual meeting platform. During the presentation, the Company will reference the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

The presentation will feature an overview of Crinetics’ key priorities and anticipated milestones for 2025. These include:

• The continued efforts to further increase commercial readiness so that the Company can rapidly provide patients in the United States with acromegaly with broad access to once-daily oral paltusotine if the new drug application is approved, with the Prescription Drug User Fee Act Target Action Date of September 25, 2025.

• The continued development of atumelnant, an investigational adrenocorticotropic hormone (ACTH) antagonist, for congenital adrenal hyperplasia (CAH) and Cushing’s disease, with Phase 3 initiation for adult CAH patients expected in the first half of 2025 and later-stage trial initiations for pediatric CAH patients and patients with Cushing’s disease expected in 2025.

• The continued advancement of Investigational New Drug-enabling studies of 4 development candidates for neuroendocrine tumors and somatostatin receptor type-2-expressing solid tumors, hyperparathyroidism, Graves’ disease, thyroid eye disease, and autosomal dominant polycystic kidney disease.

The Company’s updated corporate presentation has been posted to the Company’s website, www. crinetics. com. The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.

The information contained in this Item 7.01, including in Exhibit 99.1 hereto, is being “furnished” and shall not